Conventionally, multiparametric magnetic resonance imaging (mpMRI) incorporating T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences is considered the standard for detection and staging of clinically important prostate cancer (PCa).[1] The gallium (Ga)-labeled positron emission tomography (PET) tracer targeting prostate-specific membrane antigen (PSMA), Ga-PSMA PET, is a promising tool for detection, localization, and staging carcinoma prostate.[2] Here, we present a case of PCa, showing incongruence between Ga-PSMA PET and the corresponding mpMRI findings.
View Article and Find Full Text PDF